It’s is the end of Alzheimer’s Awareness Month, but our hope for a cure for this disease will not end.
They may not remember us, but we need to remember that Alzheimer’s battle is not theirs alone, but all of ours.
DelveInsight Blog
Trending:
FDA rejects BioMarin’s Valoctocogene...
Aug 20, 2020
FDA rejects BioMarin's gene therapy and Gilead's filgotinib over concerns The FDA refused to approve BioMarin's hemop...
Gilead’s remdesivir trials; F2G rais...
Aug 13, 2020
Researchers call out Gilead over the diversity of remdesivir trials Researchers have challenged the sponsors of COVID...
Roche-UCB’s $120M collaboration; Ome...
Jul 30, 2020
Roche bets USD 120 Million on UCB's anti-tau Alzheimer's antibody The Swiss pharma, Roche, is handing over USD 120 mi...
Sign Up and Stay Informed
Penetrative insights and rich analysis of Pharma, Biotech and MedTech space.
Editor's Pick
Commercial Roadmap for the Launch: What can Biopharmaceuticals do to Increase...
The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...
Emerging Market for Organ on a Chip
The organ on a chip is a microfluidic culture device that recapitulates the complicated...
Global Top Players in Intraocular Lens (IOL) Market
An Intraocular Lens implant is a synthetic, artificial lens placed inside the eye...
Investigating the Pipeline for Ankylosing Spondylitis Treatment Landscape
Ankylosing Spondylitis is a form of arthritis that primarily affects the spine. It caus...
LAG 3: A Promising Next Generation Cancer Immunotherapy
Immunotherapy also called biologic therapy, is a type of cancer treatment that boosts t...
RECENT ARTICLES
.png)
